69C Stock Overview
A development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.27 |
| 52 Week High | US$1.13 |
| 52 Week Low | US$0.18 |
| Beta | 0.68 |
| 11 Month Change | 28.68% |
| 3 Month Change | -8.79% |
| 1 Year Change | -70.16% |
| 33 Year Change | -97.61% |
| 5 Year Change | -98.86% |
| Change since IPO | -97.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 69C | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -14.3% | 1.4% | 0.8% |
| 1Y | -70.2% | -18.4% | 9.1% |
Return vs Industry: 69C underperformed the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 69C underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 69C volatility | |
|---|---|
| 69C Average Weekly Movement | 17.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 69C's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 69C's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 55 | Chris Posner | www.caratherapeutics.com |
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
Cara Therapeutics, Inc. Fundamentals Summary
| 69C fundamental statistics | |
|---|---|
| Market cap | €15.95m |
| Earnings (TTM) | -€91.02m |
| Revenue (TTM) | €8.28m |
1.9x
P/S Ratio-0.2x
P/E RatioIs 69C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 69C income statement (TTM) | |
|---|---|
| Revenue | US$8.69m |
| Cost of Revenue | US$111.11m |
| Gross Profit | -US$102.42m |
| Other Expenses | -US$6.90m |
| Earnings | -US$95.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | -1,179.18% |
| Net Profit Margin | -1,099.76% |
| Debt/Equity Ratio | 5,740.2% |
How did 69C perform over the long term?
See historical performance and comparison